NextNRG Amends PRE 14C to Add $30M Toxic Preferred Financing and Massive CEO Equity Package
NXXT sits 39% above its 52-week low of $0.203 on light trading volume (0.1× avg).
Summary
NextNRG's amended PRE 14C adds a $30M toxic preferred stock financing with a floor price of $0.135 (potential 30.6% dilution) and a CEO equity package worth millions, including 10% of outstanding shares at market-cap milestones, amid a going-concern warning and delisting risk.
Key Events · Financing and Capital Events · NXXT
-
Series C Toxic Preferred Financing
The board approved up to $30M in Series C Convertible Non-Voting Preferred Stock, with an initial $9M closing. Shares convert at $0.75 (initial) or lower, with a floor price of $0.135 — a deep discount to today's $0.283. At the floor, conversion of the initial 1M shares would issue up to 74M common shares, representing ~30.6% dilution to existing holders.
-
CEO Equity Package Worth Millions
Michael Farkas' employment agreement grants $2M/year in equity salary, up to 100% equity performance awards, market-cap bonuses of 10% of outstanding shares at each of five thresholds (up to $8B), and an $8.16M signing bonus in restricted stock — all subject to shareholder approval.
-
Going Concern and Delisting Risk
The company has a going-concern warning, critically low cash, and a Nasdaq delisting notice (bid price below $1.00). The reverse stock split proposal (1:5 to 1:12) is intended to regain compliance, but the new financing and equity grants add massive dilution and insider enrichment amid distress.
-
Effective Date and Next Steps
The actions become effective 20 calendar days after the definitive information statement is mailed. The Board retains discretion to abandon any proposal. The Series C Financing requires additional information statements for subsequent closings.
Analysis · NXXT · Trade & Services
This amended preliminary information statement introduces two highly dilutive and governance-red-flag proposals absent from the original July 31 filing. First, a Series C Convertible Non-Voting Preferred Stock financing of up to $30 million, with an initial $9 million closing, carries a 12.5% dividend, a conversion price as low as $0.135 (versus today's $0.283), and potential dilution of up to 74 million shares — roughly 30.6% of the current outstanding. The floor price sits deeply below market, and the structure includes redemption penalties and anti-dilution features typical of toxic death-spiral financing. Second, a CEO employment agreement for Michael Farkas grants him $2 million per year in equity salary, up to 100% equity performance awards, market-cap bonuses of 10% of outstanding shares at each of five thresholds (up to $8 billion), and an $8.16 million signing bonus in restricted stock — all while the company faces a going-concern warning, critically low cash, and a stock price near its lows. Together, these proposals signal extreme desperation for capital and a massive transfer of value from existing shareholders to insiders and new investors, compounding the already severe financial distress.
How filings like this one have moved
In the 30 days to Oct 22, 2026, 46.1% of the 284 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.53%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, NXXT was trading at $0.28 on NASDAQ in the Trade & Services sector, with a market capitalization of approximately $48.8M. The 52-week trading range was $0.20 to $2.88. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.